secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vincerx Pharma, Inc. (—)
CIK:        0001796129
Form:       8-K
Filed at:   2024-05-14T23:59:59+00:00
Accession:  0001193125-24-138272
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vincerx Pharma Q1 2024 net loss $12.4M ($0.58/sh); cash $5.1M plus $17.8M financing through 2024
--------------------------------------------------------------------------------

- Cash $5.1M at Mar 31, 2024; April financing of ~$17.8M extends runway through 2024.
- Net loss $12.4M ($0.58/sh) vs $14.6M ($0.69/sh) in Q1 2023; R&D spend $4.6M down from $10.9M.
- VIP943 Phase 1 in fourth cohort; no dose-limiting toxicities in 11 pts; preliminary PK shows minimal circulating payload.
- Enitociclib NIH combo study: four PRs in PTCL and one PR in tFL monotherapy; 63 pts enrolled overall.
- VIP236 Phase 1 signs of tumor reduction and improved safety profile; updated data expected by end of Q3 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1796129/000119312524138272/0001193125-24-138272-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1796129/000119312524138272/d825581d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-138272

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer